GNCA vs. HTGMQ, KLDO, VIVE, AHPI, NOVN, NOVNQ, HGEN, GNCAQ, VECT, and IGNY
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include HTG Molecular Diagnostics (HTGMQ), Kaleido Biosciences (KLDO), Viveve Medical (VIVE), Allied Healthcare Products (AHPI), Novan (NOVN), NVN Liquidation (NOVNQ), Humanigen (HGEN), Genocea Biosciences (GNCAQ), VectivBio (VECT), and Ignyte Acquisition (IGNY). These companies are all part of the "medical" sector.
Genocea Biosciences (NASDAQ:GNCA) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.
HTG Molecular Diagnostics' return on equity of 0.00% beat Genocea Biosciences' return on equity.
0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Genocea Biosciences had 2 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 2 mentions for Genocea Biosciences and 0 mentions for HTG Molecular Diagnostics. Genocea Biosciences' average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.
HTG Molecular Diagnostics has higher revenue and earnings than Genocea Biosciences.
Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500.
Genocea Biosciences received 388 more outperform votes than HTG Molecular Diagnostics when rated by MarketBeat users.
Summary
HTG Molecular Diagnostics beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
